Novo Nordisk: AWARD-6 is out with no surprises: and now ?
BUY, Fair Value DKK257 vs. DKK245 (-2%)
Alten: FY13 op. margin slightly above expectations, solid free cash flow
NEUTRAL, Fair Value EUR35 (-4%)
Atos to sign a long-term agreement with a Russian IT JV
BUY, Fair Value EUR76 (+13%)
Sopra Group: Feedback from Paris roadshow
BUY, Fair Value EUR101 (+10%)
Atos: FY13 results in line, FY14 guidance a bit light on the margin
BUY, Fair Value EUR76 (+9%)